Why this caught my eye
That is a bold promise, so I did what I usually do: read the site, dig into the published research behind it, and look for what outside researchers say. Here is what I found, the good and the not-so-good.
What Vero is actually offering
Vero sells three related things, and only one of them exists today.
- OrganAge™: a blood test that reads more than 11,000 plasma proteins and returns a separate age for 10+ organs, plus where each stands against people your age.
- Cell Clocks™: the same idea at the cell-type level. The underlying paper modelled over 40 cell types from 60,542 people and found that 20 to 25 percent of individuals showed accelerated aging in a single cell type.
- Vero Compass™: a planned platform that combines your result with clinical, wearable and lifestyle data to suggest interventions. Vero says it is in development, research-only, and not a diagnosis or treatment plan.
Availability is limited. The FAQ says OrganAge is currently offered only through select clinical research partnerships, with broad consumer availability planned for 2027. The waitlist is free, and I could not find a price anywhere on the site.
How the science works
Proteomics means measuring the proteins circulating in your blood. Your genome is a fixed instruction set; your proteome shows what your body is producing right now, and it shifts with age, illness, sleep, training and stress.
The tricky part is that a protein in blood does not say which organ it came from. Vero’s approach, per its FAQ, links proteins to organs statistically using gene expression atlases. A protein counts as organ-enriched when one tissue makes it at several times the rate of any other. In the 2023 Nature study, 856 of 4,778 proteins cleared that bar.
Once each organ has its protein set, a model compares your pattern with people your age and calculates an “age gap.” Vero also contrasts this with DNA methylation clocks, which read slow-moving chemical marks on DNA and give one overall score. Its argument is that methylation in blood is hard to trace to a specific organ, while organ-enriched proteins are not.
The evidence base is three peer-reviewed papers, all from the Wyss-Coray lab:
- Nature, 2023: 5,676 adults aged 27 to 104 across five cohorts, modelling 11 organs.
- Nature Medicine, 2025: roughly 44,500 UK Biobank participants, where brain age was the strongest single predictor of mortality risk in that dataset.
- Nature Medicine, 2026: the Cell Clocks work in 60,542 people.
Vero is upfront that these are association studies in large cohorts, not clinical trials.
What I like
- Serious, published science. The core work sits in Nature and Nature Medicine, with cohorts in the tens of thousands, not a small pilot.
- Independent groups are building similar tools. A separate Nature Aging paper built its own organ clocks across ten organ systems using 43,616 UK Biobank participants and reported they predict disease and mortality. It also notes that earlier organ clocks often reflected whole-body aging more than organ-specific aging.
- Honest about its limits. The FAQ says the test cannot diagnose or rule out disease, does not replace screening or your physician, and will not explain why an organ reads older.
- A sensible framing. Vero positions it as something you bring to your clinician alongside an annual physical, not a substitute.
- Low-pressure entry. Joining the waitlist is free and carries no obligation.
What gives me pause
- Prediction is not intervention. The studies show that organ age gaps are associated with future disease and mortality. They do not show that changing your score changes your outcome, and Vero’s promise of targeted interventions through Compass is still future-tense.
- Proteomic clocks have limited clinical validation. A recent phase 2a trial analysis notes that most of these clocks have seen scarce validation in clinical settings. It also says they cannot separate general aging effects from disease-specific ones.
- Organ attribution is inferred. A study of cognition and organ clocks reported small effect sizes and noted that protein-to-organ annotations remain putative, especially for the brain, given open questions about the blood-brain barrier. The Nature Aging authors likewise say the brain clock needs validation with absolute rather than relative protein measurements.
- Different clocks can disagree. A review of alcohol and organ clocks found substantial discrepancies between studies on how drinking relates to aging in specific organs.
- Close ties between the science and the company. The lead researcher is a Vero co-founder, and the “as seen in” strip leans on prestige logos, including a Nature link that points to the lab’s own paper. That is normal for a startup, but it means the strongest claims deserve outside replication.
- Unknowns for a consumer. I found no price, no retest guidance, no information on what a result looks like in practice, and no timeline beyond “2027.” The dashboard mockup on the homepage shows a tidy 96/100 “Resilient” brain score, which looks more definitive than the underlying statistics probably are.
My take
The idea is compelling and the research is real. Organ-level aging signals from a blood sample could be a genuinely useful research tool, and the evidence for risk prediction at the population level looks solid.
What I cannot say yet is whether a single person’s result is actionable. Until there is evidence that acting on an organ-age reading improves outcomes, I see OrganAge as interesting information to discuss with a doctor, not a guide to changing how I live.
I will be watching for three things: independent replication, published results from Vero’s clinical partnerships, and a clear price and report format when 2027 arrives. If you are curious, the waitlist costs nothing.
Sources
- Vero homepage, FAQ and About
- Organ aging signatures in the plasma proteome track health and disease, Nature, 2023
- Plasma proteomics links brain and immune system aging with healthspan and longevity, Nature Medicine, 2025
- Plasma proteomic signatures of cellular aging predict human disease, Nature Medicine, 2026
- Organ-specific proteomic aging clocks predict disease and longevity across diverse populations, Nature Aging
- Integration of proteomic aging clocks in a phase 2a clinical trial
- Organ-specific proteomic aging and cognitive performance
- Organ-specific clocks and the healthy drinking paradox
